Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.21 (market cap $17.89B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 8.4× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HYG | RXRX | |
|---|---|---|
Market Cap | $17.89B | $2.14B |
Volume | 44,866,592 | 30,789,535 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $6.79 |
52-Week Low | $76.90 | $2.84 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.18, down 0.12% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces pressure from rising Treasury yields impacting high-yield bond valuations. Recent dividend payments of $0.34-$0.44 provide income support amid market volatility.
The outlook remains challenged by persistent bond market selloffs and higher interest rates, though the current yield environment may attract income-seeking investors. Key risks include further Fed tightening and economic slowdown impacting corporate credit quality.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
